Literature DB >> 22078168

Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview.

John C Morris1, Dennis J Selkoe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22078168     DOI： 10.1016/j.neurobiolaging.2011.09.005

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN： 0197-4580            Impact factor:   4.673


× No keyword cloud information.
  12 in total

1.  Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years.

Authors:  Suzanne E Schindler; Courtney L Sutphen; Charlotte Teunissen; Lena M McCue; John C Morris; David M Holtzman; Sandra D Mulder; Philip Scheltens; Chengjie Xiong; Anne M Fagan
Journal:  Alzheimers Dement       Date:  2017-07-12       Impact factor: 21.566

2.  Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.

Authors:  Anna Caroli; Annapaola Prestia; Sara Wade; Kewei Chen; Napatkamon Ayutyanont; Susan M Landau; Cindee M Madison; Cathleen Haense; Karl Herholz; Eric M Reiman; William J Jagust; Giovanni B Frisoni
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Apr-Jun       Impact factor: 2.703

3.  Preclinical Alzheimer disease and risk of falls.

Authors:  Susan L Stark; Catherine M Roe; Elizabeth A Grant; Holly Hollingsworth; Tammie L Benzinger; Anne M Fagan; Virginia D Buckles; John C Morris
Journal:  Neurology       Date:  2013-06-26       Impact factor: 9.910

4.  Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes.

Authors:  Soyon Hong; Beth L Ostaszewski; Ting Yang; Tiernan T O'Malley; Ming Jin; Katsuhiko Yanagisawa; Shaomin Li; Tim Bartels; Dennis J Selkoe
Journal:  Neuron       Date:  2014-03-27       Impact factor: 17.173

5.  Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.

Authors:  Leon M Tai; Tina Bilousova; Lisa Jungbauer; Stephen K Roeske; Katherine L Youmans; Chunjiang Yu; Wayne W Poon; Lindsey B Cornwell; Carol A Miller; Harry V Vinters; Linda J Van Eldik; David W Fardo; Steve Estus; Guojun Bu; Karen Hoppens Gylys; Mary Jo Ladu
Journal:  J Biol Chem       Date:  2013-01-04       Impact factor: 5.157

6.  Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.

Authors:  Suzanne E Schindler; Julia D Gray; Brian A Gordon; Chengjie Xiong; Richard Batrla-Utermann; Marian Quan; Simone Wahl; Tammie L S Benzinger; David M Holtzman; John C Morris; Anne M Fagan
Journal:  Alzheimers Dement       Date:  2018-03-02       Impact factor: 21.566

Review 7.  Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.

Authors:  Victor L Villemagne; Vincent Doré; Samantha C Burnham; Colin L Masters; Christopher C Rowe
Journal:  Nat Rev Neurol       Date:  2018-02-16       Impact factor: 42.937

Review 8.  EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease.

Authors:  Leon M Tai; Deebika Balu; Evangelina Avila-Munoz; Laila Abdullah; Riya Thomas; Nicole Collins; Ana Carolina Valencia-Olvera; Mary Jo LaDu
Journal:  J Lipid Res       Date:  2017-04-07       Impact factor: 5.922

9.  Clinical trial design of serious gaming in mild cognitive impairment.

Authors:  Cristina Muscio; Pietro Tiraboschi; Ugo P Guerra; Carlo A Defanti; Giovanni B Frisoni
Journal:  Front Aging Neurosci       Date:  2015-03-11       Impact factor: 5.750

10.  Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging.

Authors:  Alison A Motsinger-Reif; Hongjie Zhu; Mitchel A Kling; Wayne Matson; Swati Sharma; Oliver Fiehn; David M Reif; Dina H Appleby; P Murali Doraiswamy; John Q Trojanowski; Rima Kaddurah-Daouk; Steven E Arnold
Journal:  Acta Neuropathol Commun       Date:  2013-06-27       Impact factor: 7.801
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.